Regenxbio Investor Relations Material
Latest events
Status Update
Regenxbio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Regenxbio Inc
Access all reports
REGENXBIO is a clinical-stage biotechnology company that provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
RGNX
Country
🇺🇸 United States